Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Impetigo Clinical Trial

Official title:

A Randomized, Parallel-group, Double Blind, Clinical Trial, to Assess the Safety and Efficacy of Topically Applied FXFM244 Antibiotic Foam in the Treatment of Impetigo

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01171326
• Other study ID #: 005-10LND /FX2010-01
• Status: Completed
• Phase: Phase 2
• First received: July 27, 2010
• Last updated: December 9, 2013
• Start date: August 2010
• Est. completion date: April 2012

Study information

• Verified date: December 2010
• Source: Foamix Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Institutional Review Board - Laniado Hospital
• Study type: Interventional

Clinical Trial Summary

Impetigo is a common, highly infectious skin disease caused by bacterial infection and characterized by crusting skin lesions. It is most common in children, particularly children in unhealthy living conditions. In adults, it may follow other skin disorders. Impetigo is caused primarily by the bacteria Streptococcus pyogenes and/or Staphylococcus aureus, which can also be isolated from impetigo lesions.

This is a pilot phase II study to evaluate the tolerability and safety and to monitor the clinical efficacy of Topical Minocycline Foam FXFM244 in impetigo patients.

Description:

A randomized, parallel-group, double (Investigator, patient) blind, comparative dose range finding clinical trial.

The study will involve two treatment groups. Eligible patients will be randomized to receive either FXFM244 - 1%, FXFM244 - 4% , in a blinded fashion. Patients will be treated twice daily for 7 days. Following the screening period and baseline visit, study subjects will return at days 3, 7 and 14. At each visit, patients will be evaluated via lesion count, global assessment tolerability and safety.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: April 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Patients with clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering impetigo

• Patients 2 years of age or older, and in general good health

• Patients with no less than two lesions and no more than seven lesions, area 0.5x0.5cm.

• No known medical conditions that, in the Investigator's opinion could interfere with study participation

• Patient / Patient's guardian (in the case of children) willing and able to comply with all requirement of the protocol

• Patient / Patient's guardian willing and able to give written informed consent prior to participation in the study

Exclusion Criteria:

• Presence of skin diseases at or near the investigational area

• Immunosuppressed state or other serious systemic disease

• Signs and/or symptoms of systemic infection

• Presence of skin infection/disorder not amenable to topical antibacterial treatment only

• Presence of secondarily-infected animal/human bite

• Presence of secondarily infected burn wound

• Topical or systemic use of medicinal or other products before or during the study (oral or topical antibiotics, oral or topical corticosteroids and immuno modulators); or other drugs, which in the Investigators opinion could confound the evaluation of the effect of the study drugs

• Known or suspected hypersensitivity to Minocycline or any of the excipients in the study medication

• Participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomization

• Patients previously enrolled/randomized in this study

• Use of another investigational drug within 30 days prior to entry into this study.

• Pregnant or lactating women.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Impetigo

Intervention

Drug:
• Topical Minocycline Foam FXFM244
FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days

Locations

Country	Name	City	State
Israel	Lev Yasmin Clinic	Natanya

Sponsors (1)

Lead Sponsor	Collaborator
Foamix Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Decrease in lesion count		7 days	Yes
Secondary	The severity of the overall impetigo condition will be measured at baseline and at all follow-up visits. The severity will be assessed and graded based on the scales for Investigator's Global Assessment and bacteriological testing.		Days 3, 7 and 14	Yes